Athersys, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel regenerative medicine products. The company’s core technology platform, known as MultiStem, is an off-the-shelf, allogeneic cell therapy designed to modulate inflammation, promote tissue repair and support immune system balance. Athersys leverages its proprietary cell-culture processes and immunomodulatory capabilities to generate therapeutic candidates for a range of serious medical conditions.
MultiStem has been evaluated in multiple clinical studies targeting acute ischemic stroke, acute respiratory distress syndrome (ARDS) and inflammatory bowel disease, among other indications. In each case, the therapy is administered intravenously, aimed at harnessing the cells’ natural ability to secrete factors that support tissue recovery and reduce detrimental immune responses. Athersys continues to optimize its manufacturing processes to ensure scalable production and consistent quality for potential commercialization.
Founded in the late 1990s and headquartered in Cleveland, Ohio, Athersys completed its initial public offering in the early 2000s and trades on the NASDAQ under the symbol ATHX. Over the years, the company has established strategic partnerships, most notably with a leading Japanese regenerative medicine firm to advance clinical development and regulatory filings in Asia. Athersys conducts research and clinical trials across North America, Europe and Asia, collaborating with academic centers, hospitals and regulatory bodies to support product development.
Under the leadership of President and Chief Executive Officer Gil Van Bokkelen, Athersys is committed to advancing its pipeline and bringing innovative cell therapies to patients worldwide. The company continues to pursue regulatory approvals and partnership opportunities to expand the reach of its MultiStem platform, with the aim of addressing unmet medical needs in acute and chronic disease areas.
AI Generated. May Contain Errors.
